問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間:2023-09-19

錢穎群
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

105Cases

2020-04-01 - 2025-11-26

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting4Sites

Terminated1Sites

2020-06-01 - 2022-05-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2020-06-20 - 2027-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2020-07-01 - 2026-06-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2020-09-15 - 2025-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2021-01-04 - 2026-03-31

Others

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Terminated6Sites

2021-05-31 - 2026-09-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
A phase IIb trial (ARGiNAUT) evaluating the efficacy, safety, and tolerability of AZD8965 in patients with idiopathic pulmonary fibrosis (IPF).
  • Condition/Disease

    Idiopathic pulmonary fibrosis

  • Test Drug

    AZD8965 Film-Coated Tablet

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-12-23 - 2024-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-01-01 - 2026-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites